Summary of Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2022

Summary of Significant Accounting Policies

Schedule of reconciliation of the cash, cash equivalents and restricted cash amounts

	March 31, 2022		March 31, 2021
Cash and cash equivalents	$	106,108	$	81,290
Restricted cash, included in other assets		5,000		5,000
Cash, cash equivalents and restricted cash as presented on the Consolidated Statements of Cash Flows	$	111,108	$	86,290

Schedule of the Company's net sales by medical indication

	Three Months Ended				Nine Months Ended
(In thousands)	March 31,				March 31,
Medical Indication	2022		2021		2022		2021
Analgesic	$	3,292	$	3,836	$	12,525	$	10,528
Anti-Psychosis		3,346		11,678		9,156		38,023
Cardiovascular		9,468		16,573		33,321		52,623
Central Nervous System		15,177		24,509		60,302		71,648
Endocrinology		6,792		6,822		22,934		19,551
Gastrointestinal		11,709		16,817		40,972		52,492
Infectious Disease		5,438		10,610		24,473		55,586
Migraine		3,507		5,169		12,638		20,942
Respiratory/Allergy/Cough/Cold		2,309		2,548		7,291		6,241
Urinary		827		1,566		3,167		4,385
Other		13,873		8,617		32,160		24,661
Contract manufacturing revenue		2,619		3,625		7,451		16,089
Total net sales	$	78,357	$	112,370	$	266,390	$	372,769

Summary of products which accounted for at least 10% of total net sales

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2022		2021		2022		2021
Product 1	5	%	8	%	7	%	13	%

Summary of customers which accounted for at least 10% of total net sales

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2022		2021		2022		2021
Customer A	19	%	20	%	18	%	21	%
Customer B	17	%	29	%	25	%	27	%
Customer C	12	%	13	%	14	%	12	%